Physicians are sometimes reluctant to initiate guideline-directed therapy in patients with heart failure and reduced ejection fraction (HFrEF) due to concerns of adverse events. We explored the risk of hypotension, volume depletion, and acute kidney injury (AKI) on sodium–glucose cotransporter 2 (SGLT2) inhibitors in HFrEF populations.

中文翻译：

---

钠-葡萄糖协同转运蛋白 2 抑制剂治疗心力衰竭的副作用和治疗启动障碍：系统评价和荟萃分析

由于担心不良事件，医生有时不愿意对心力衰竭和射血分数降低 (HFrEF) 患者启动指南指导的治疗。我们探讨了钠-葡萄糖协同转运蛋白 2 (SGLT2) 抑制剂在 HFrEF 人群中发生低血压、血容量不足和急性肾损伤 (AKI) 的风险。